Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor monotherapy after coronary stenting in acute myocardial infarction
2024-514224-17-00Phase 2Completed
- Sponsor
- Region Västra Götaland
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ticagrelor in myocardial infarction (MI), sponsored by Region Västra Götaland. Primary endpoint: Composite of cardiac death, spontaneous myocardial infarction or definite or probable stent thrombosis within 3 months. Started Jun 2024; status: completed.
02
Drugs
ticagrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2024-514224-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514224-17-00.